CSP
IBB icon

Cary Street Partners’s iShares Biotechnology ETF IBB Stock Holding History

Cary Street Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.8K Buy
330
+156
+90% +$26.8K ﹤0.01% 1035
2026
Q1 		$29.4K Hold
174
– – ﹤0.01% 956
2025
Q4 		$29.4K Buy
+174
New +$28.3K ﹤0.01% 954

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Cary Street Partners's IBB Position: Q2 2026 in Review

Cary Street Partners increased its iShares Biotechnology ETF (IBB) stake by 90% in Q2 2026, buying an estimated $26.8K and bringing the position to 330 shares worth $62.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

Cary Street Partners first reported a position in IBB in Q4 2025 and has held it in 3 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Cary Street Partners held 330 shares of iShares Biotechnology ETF worth $62.8K as of Q2 2026.
  • Cary Street Partners bought 156 iShares Biotechnology ETF shares in Q2 2026, an estimated $26.8K.
  • iShares Biotechnology ETF made up ﹤0.01% of Cary Street Partners's portfolio in Q2 2026, its #1035 holding.
  • Cary Street Partners first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.